CAR-T Kidney Care: Anticipate Systemic Toxicity

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Track kidney recovery and persistent electrolyte abnormalities. Do not carry forward unverified product indications or mechanistic claims from a rapidly evolving field.

Track inflammation and organ function together. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Track inflammation and organ function together. Cellular therapy — Record treatment timing; Systemic signs — Fever, pressure and oxygen needs; Kidney / electrolyte changes — Assess multiple possible causes; Coordinated escalation — Cellular-therapy and organ-support teams. Onset varies. This sequence does not assign one fixed day to toxicity. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Immune activation affects organs

Cellular therapy can trigger inflammatory syndromes with hemodynamic instability and kidney stress. AKI may also reflect infection, drugs, tumor lysis, or prior disease.

Recognize CRS with ASTCT criteria

CRS begins with fever ≥38°C not explained by another cause; severity is determined by the more severe hypotension or oxygen-support requirement. Once anti-cytokine or antipyretic treatment has begun for CRS, fever is not required for subsequent grading. Infection can coexist and still requires evaluation.

Keep alternatives active

Cytokine-release syndrome and infection can overlap. Evaluate perfusion, cultures, medications, electrolyte changes, and tumor burden rather than assigning every AKI to one cause.

Coordinate with the cellular-therapy team

Use the current product-specific and institutionally approved grading and treatment pathway. Renal dose adjustment and supportive care require shared decisions.

Explain the electrolyte abnormality

For falling potassium or phosphate, assess intake, gastrointestinal loss, drugs, renal wasting, and intracellular shifts. B-cell depletion is not a valid explanation based on loss of the body’s potassium stores. Replace according to severity and kidney function while monitoring magnesium, rhythm, and ongoing losses.

Follow beyond the acute phase

Track kidney recovery and persistent electrolyte abnormalities. Do not carry forward unverified product indications or mechanistic claims from a rapidly evolving field.

Supporting evidence

Continue learning